Overview

Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:
0

Participant gender:
All

Summary

The improvement of conventional imaging techniques has led to an increased detection rate of different adrenal tumors. Since those tumors can belong to a variety of entities the therapeutic consequences also show considerable variation. In order to definitely determine the type of tumor, invasive procedures like CT guided biopsies are often required, which could be avoided by a tumor specific imaging method. The presently available scintigraphic procedures are either time consuming and lead to high radiation exposure or are technically demanding. The steroidogenic enzymes CYP11B1 (11ß-hydroxylase)and CYP11B2 (aldosterone synthase)are expressed exclusively in the adrenal cortex and therefore represent suitable targets for a specific imaging technique. In our project we evaluate 123I-Iodometomidate which binds to both CYP11B enzymes as radiotracer for adrenal scintigraphy.

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Wuerzburg

Treatments:

Etomidate

Criteria

Inclusion Criteria:

1. Adrenal tumor seen by CT or MRT-scan with diameter of at least 2 cm or patient with
adrenocortical carcinoma and suspected metastasis or local recurrence or patients with
primary hyperaldosteronismus and adrenal tumour > 1 cm

2. Hormonal work up of of the adrenal tumor according to ENS@T (European network for the
study of adrenal tumours)-criteria

3. Age ≥ 30 Jahre

4. Effective contraception (pearl index <1%)

5. Written informed consent

Exclusion Criteria:

1. Pregnancy or breast feeding

2. Renal insufficiency (serum creatinine > 2,0 mg/dl or MDRD < 60 ml/min)

3. Known allergy to etomidate or constituents of the test drug